Zanzalintinib in combination with immune checkpoint inhibitors: Design of the renal cell carcinoma expansion stage cohorts in STELLAR-002

Background: Zanzalintinib (XL092) is a novel, potent, orally bioavailable small molecule inhibitor of several receptor tyrosine kinases, including VEGFR2, MET, and the TAM kinases AXL, and MER. These receptor tyrosine kinases are implicated in several oncogenic processes, including tumor angiogenesi...

Descripción completa

Detalles Bibliográficos
Autores principales: Motzer, Robert J, Choueiri, Toni K, Garmezy, Benjamin, O’Neil, Bert, Michalski, Joel, Barata, Pedro, Bajaj, Aung, Chahoud, Jad, Liu, Mohan, Xu, Fiona, Andrianova, Svetlana, Shah, Neil, McGregor, Bradley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Trials in Progress Abstract Presentations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445562/
http://dx.doi.org/10.1093/oncolo/oyad216.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445562/
http://dx.doi.org/10.1093/oncolo/oyad216.016

Ejemplares similares